Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Bob Swift who wrote (1421)	11/12/1998 4:35:00 PM
From: BMcV	Read Replies (2) \| Respond to of 10280

Oxy data on SEPR website: biz.yahoo.com Thursday November 12, 1:46 pm Eastern Time (S)-Oxybutynin Data Show Reduction In Frequency And Incontinence Phase II Data Now Available on Sepracor Web Site MARLBOROUGH, Mass., Nov. 12 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR - news) today announced that results of the Phase II (S)-oxybutynin study will be available on the Company's web site located at www.sepracor.com after 3:00 p.m. Eastern Standard Time. To access the information, enter into the Investors section and then access the Presentations segment. Detailed results of the two-week, double-blind, randomized, placebo- controlled, pilot trial that was designed to evaluate the efficacy of two doses of (S)-oxybutynin in the treatment of symptoms associated with urge urinary incontinence are posted. This study demonstrated (S)-oxybutynin's ability to reduce urinary frequency and episodes of involuntary urination (incontinence). (S)-oxybutynin was also well tolerated with only 14-16 percent of patients experiencing moderate-severe dry mouth. Maybe someone with some expertise can go take a look? Bruce